Swedish company AlzeCure Pharma presents ACD856's potential to modify Alzheimer's disease at CTAD Madrid conference.

AlzeCure Pharma, a Swedish company focused on nervous system diseases, announced that its abstract on ACD856's anti-inflammatory and immunomodulatory effects will be presented at the CTAD conference in Madrid. New preclinical results suggest ACD856 may have disease-modifying potential for Alzheimer's. CEO Martin Jönsson expressed satisfaction in sharing these promising findings at the conference.

October 01, 2024
4 Articles

Further Reading